Previously, no more than 8 IgG anti-Rh(D) human MoAbs have been derived from a single individual. 10 The primary challenge in studying the Rh(D) immune response has been technical difficulties inherent in human B-cell immortalization. Epstein-Barr virus (EBV) transformation results in relatively low transformation efficiencies 11 that can undergo a decline in antibody production, 12-15 whereas cell fusion methods have been hampered by the lack of good fusion partners. 16, 17 More recently, molecular approaches have been developed that bypass the need for cell transformation. [18] [19][20] Conceptually, these techniques, referred to as repertoire cloning or Fab/phage display, seek to immortalize Ig mRNA rather than the B cells from which they were derived. In an earlier report, our laboratory adapted these techniques for isolating Fab/phage antibodies directed against conformation-dependent antigens expressed on cell surfaces. 21 Using intact human RBCs, we isolated highly diverse ␥ 1 and ␥ 1 Fab/phage libraries against the Rh(D) antigen from the B cells of a single Rh(D)-immune globulin donor. 22 In the following report, we present a detailed genetic and serological analysis of 53 unique anti-Rh(D) antibodies derived from 83 randomly chosen clones. The results complement previous reports on the genetic and biochemical makeup of monoclonal anti-Rh(D) antibodies derived from multiple donors. 10, [23][24] [25] Significantly, our data also demonstrate extensive genetic homology between antibodies directed against different Rh(D) epitopes. We provide evidence that antibodies directed against different epitopes can be clonally related. Finally, we suggest a model that reconciles the serological diversity of anti-Rh(D) antibodies with the topological constraints imposed by the Rh(D) antigen.
C
LINICALLY, THE HUMAN Rh(D) antigen is the most important red blood cell (RBC) membrane protein in transfusion medicine. The alloimmune response against Rh(D) produces high-affinity IgG antibodies that cause hemolytic transfusion reactions and hemolytic disease of the newborn (HDN). The prophylactic use of Rh(D)-immune globulin in pregnant Rh(D)-negative women has been a major advance in the prevention of HDN, 1 yet the mechanism by which the drug exerts its immune modulatory effect is not well understood. 2 Monoclonal antibodies (MoAbs) derived from the B cells of Rh(D)-immune globulin donors have defined several dozen Rh(D) epitopes 3 ; paradoxically, the Rh(D) antigen, an approximately 30-kD transmembrane protein, has minimal extracellular mass and presents a very limited surface area for epitope expression. [4] [5] [6] [7] [8] [9] The molecular cloning of large repertoires of anti-Rh(D) antibodies would help reconcile these observations. In addition, it would facilitate the rational development of recombinant formulations of Rh(D)-immune globulin and aid in the design of therapeutic agents that block antibody binding. Furthermore, the comprehensive genetic analysis of anti-Rh(D) antibodies within a given alloimmunized individual would serve as a paradigm for human immune repertoire development, an area in which limited information is currently available.
Previously, no more than 8 IgG anti-Rh(D) human MoAbs have been derived from a single individual. 10 The primary challenge in studying the Rh(D) immune response has been technical difficulties inherent in human B-cell immortalization. Epstein-Barr virus (EBV) transformation results in relatively low transformation efficiencies 11 that can undergo a decline in antibody production, 12-15 whereas cell fusion methods have been hampered by the lack of good fusion partners. 16 , 17 More recently, molecular approaches have been developed that bypass the need for cell transformation. [18] [19] [20] Conceptually, these techniques, referred to as repertoire cloning or Fab/phage display, seek to immortalize Ig mRNA rather than the B cells from which they were derived. In an earlier report, our laboratory adapted these techniques for isolating Fab/phage antibodies directed against conformation-dependent antigens expressed on cell surfaces. 21 Using intact human RBCs, we isolated highly diverse ␥ 1 and ␥ 1 Fab/phage libraries against the Rh(D) antigen from the B cells of a single Rh(D)-immune globulin donor. 22 In the following report, we present a detailed genetic and serological analysis of 53 unique anti-Rh(D) antibodies derived from 83 randomly chosen clones. The results complement previous reports on the genetic and biochemical makeup of monoclonal anti-Rh(D) antibodies derived from multiple donors. 10, [23] [24] [25] Significantly, our data also demonstrate extensive genetic homology between antibodies directed against different Rh(D) epitopes. We provide evidence that antibodies directed against different epitopes can be clonally related. Finally, we suggest a model that reconciles the serological diversity of anti-Rh(D) antibodies with the topological constraints imposed by the Rh(D) antigen.
MATERIALS AND METHODS

Production of Monoclonal Anti-Rh(D) Phage-Displayed and Soluble Fab Molecules
Methods for the isolation of human anti-Rh(D)-specific antibodies from ␥ 1 and ␥ 1 Fab/phage display libraries using the pComb3H phagemid vector and a cell-surface panning protocol have been previously published. 22 Soluble anti-Rh(D) Fab preparations for inhibition studies were produced from bacterial cultures transfected with plasmid DNA from which the M13 gene III coat protein sequence had been excised as described. 21, 26 Cultures were grown by shaking at 300 RPM at 37°C in superbroth (30 g/L tryptone, 20 g/L yeast, 10 g/L MOPS, pH 7.00) containing 20 mmol/L MgCl 2 and 50 µg/mL carbenicillin to an OD 600 of 0.5. Isopropyl-␤-D-thiogalactopyranoside (IPTG) was added to 1 mmol/L and cultures were shaken overnight at 30°C. Bacterial pellets were harvested and resuspended in 1/50th of the initial culture volume with osmotic shock buffer (500 mmol/L sucrose, 1 mmol/L EDTA, 100 mmol/L Tris, pH 8.00), incubated for 30 minutes at 4°C, and centrifuged at 16,000g for 15 minutes at 4°C. Fab-containing supernatants were dialyzed against phosphate-buffered saline (PBS) and used in agglutination experiments without further purification.
Anti-Rh(D) Antibody Binding Assays
The binding of anti-Rh(D) Fab/phage or soluble Fab molecules to normal or partial Rh(D) antigens was assessed by indirect agglutination assays as described. 21, 22 Briefly, 100 µL aliquots of phage-displayed Fabs or soluble Fabs were incubated with 50 µL of a 3% suspension of RBCs. After 1 hour of incubation at 37°C, the RBCs were washed three times with 2 mL of cold PBS to remove unbound antibody. The resulting RBC pellets were resuspended in 100 µL of a 10 µg/mL solution of sheep anti-M13 antibody (5 Prime = 3 Prime, Boulder, CO) for Fab/phage experiments or goat antihuman or light chain antibody (Tago, Burlingame, CA) for ␥ 1 or ␥ 1 soluble Fab experiments, respectively. The RBC suspensions were transferred to the round-bottomed wells of a 96-well microplate and left undisturbed for 2 hours. Negative reactions show sharp approximately 2-mm diameter RBC spots, whereas the RBCs in agglutinated wells form a thin carpet coating the entire floor of the well. 22 Agglutination titers for recombinant antibodies were determined by performing serial twofold dilutions in 1% bovine serum albumin (BSA)/PBS. Typically, Fab/phage had agglutination titers of 1/1,024 to 1/2,048 (where neat is defined as 5 ϫ 10 12 tfu/mL), 22 Inhibition experiments were also performed using pairwise combinations of soluble Fabs instead of soluble Fab and Fab/phage combinations. In this type of experiment, pairs of soluble Fabs specific for different epitopes were chosen such that one Fab contained a light chain and the other a light chain. Incubations with RBCs were performed with one Fab in excess and the other in limiting amounts. Blocking of the latter antibody was assessed using a secondary antibody (anti-or anti-) specific for its light chain isotype.
Nucleotide Sequencing and Analysis
Plasmid DNA for sequencing was prepared using the Qiawell system (Qiagen, Chatsworth, CA). Double-stranded DNA was sequenced using light chain or heavy chain Ig constant region reverse primers or a set of unique pComb3H vector primers that anneal 5Ј to the respective Ig chain 26, 27 and automated fluorescence sequencing (Applied Biosystems, Foster City, CA; DNA Sequencing Facility, University of Pennsylvania Department of Genetics and Cancer Center, Philadelphia, PA). Sequence analysis and variable region germline assignments were performed using DNAplot 28 and the V Base Directory of Human V Gene Sequences (March 1997 update). 29 Germline assignments were corroborated with the MacVector (v. 6.0) software package (Oxford Molecular Group, Oxford, UK) against the same database. Multiple sequence alignments and predictions of isoelectric point were calculated using the Pileup and Isoelectric programs of the GCG software package (v. 8.0.1; GCG, Madison, WI). Statistical analysis was performed with Statview (Abacus Concepts, Berkeley, CA).
Because of the large number of heavy and light chain sequences (N ϭ 69), only alignments of the predicted amino acid sequences are presented. Nucleotide sequences of all clones are available in Genbank.
RESULTS
Sequence Analysis of Anti-Rh(D) Heavy and Light Chains
We previously reported on the use of Fab/phage display and cell-surface panning to isolate a large array of anti-Rh(D) antibodies from the peripheral blood lymphocytes of a single hyperimmunized donor. 22, 30 Separate ␥ 1 and ␥ 1 Fab/phage display libraries had been constructed and contained 7 ϫ 10 7 and 3 ϫ 10 8 independent transformants, respectively, based on electroporation efficiency. Each library was panned independently using a simultaneous positive/negative selection strategy with magnetically labeled Rh(D)-positive RBCs and unmodified Rh(D)-negative RBCs as described. After two rounds of panning, 32 of 36 ␥ 1 and 15 of 15 ␥ 1 randomly chosen clones were positive for anti-Rh(D) activity. After the third round of panning, 24 of 24 ␥ 1 and 12 of 12 ␥ 1 clones were positive. Nucleotide sequencing of the 83 positive clones showed a total of 28 unique heavy and 41 unique light chains. Because of combinatorial effects during phage display library construction, heavy and light chain gene segments paired to produce 53 unique Fab antibodies. 22 Anti-Rh(D) heavy chains. All of the heavy chain sequences used V H III family-encoded gene products (Figs 1 and 2 ).
Several sequences shared identical VDJ joining regions, and 12 unique VDJ rearrangements were identified and designated VDJ1 through VDJ12. Alignment of these sequences against the V Base Directory of Human V Gene Sequences 29 Fig 2B) and their next nearest neighbor, VH3-07, is only 90% homologous (Fig 2C) . Hereafter, these three genes are referred to as the VH3-33 superspecies. Heavy chain E1 differed from VH3-21 by 6 mutations and from VH3-48 by 10 mutations; hence, it was assigned to the former germline gene. Because there were no common mutations among the VH3-33 clones, it is highly probable that the donor possessed the VH3-33 germline gene. However, we could not formally rule out gene duplication with allelic variants of VH3-33 or the existence of variant alleles of the other germline genes in the donor. The isolation of clones sharing multiple VDJ joining regions argues that cloning artifacts cannot account for the V H gene restrictions observed.
Neither J H nor D segments showed restriction. At least 9 different D segments were used and J H gene use comprised J H 6 (5 VDJs and 9 clones), J H 4 (4 VDJs and 10 clones), J H 3 (2 VDJs and 8 clones), and J H 5 (1 VDJ and 1 clone). All four V H genes were Chothia class 1-3, 31 and the CDR3s showed a narrow range of length from 15 to 19 residues.
Because rearranged heavy chain genes demonstrate extensive diversity, clones sharing identical VDJ rearrangements are generally considered to have arisen from the same clone. Based on nucleotide alignment with the germline genes (data not shown), an ontogeny tree was constructed for the 12 VDJs and 28 clones (Fig 3) . By using the most parsimonious mutation scheme (ie, postulating the minimum number of mutations), putative intermediate antibodies were derived for several of the VDJs and were designated Ca, Cb, Da, Db, and Dc (Figs 2A and 3). Compared with the isolated heavy chain clones, which displayed between 6 and 23 nucleotide differences from their germline counterparts, these putative intermediates had between 3 and 12 mutations from germline. Based on the ontogeny tree, the number of independent mutations could be tabulated among the clones. The most commonly mutated residues were 52a and 58 (7 independent mutations), followed by residues 30, 31, and 50 (6 mutations) and residue 55 (5 mutations). In the VH3-33 superspecies, residues 52a and 58 in CDR2 are tyrosines and residue 52a was mutated to phenylalanine in 6 of the 11 VDJs derived from VH3-33 superspecies V H genes. Mutations at residue 58 comprised glutamate (3), aspartate (2), histidine (1), and asparagine (1). The AGY serines at residues 30, 31, and 55 were mutated to a number of different amino acids, although the AGY serine at 82b was conserved in all clones. The valine at residue 50 in the VH3-33 superspecies also had a diverse set of mutations. This distribution of hot spots is similar to that seen with nonproductive rearrangements as previously reported by Dörner et al. 32 
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Anti-Rh(D) light chains. Seventeen of the 18 light chains were from the V I family and the remaining light chain originated from a V II family member germline gene (Fig 4) . Only 4 V germline genes were used (15 clones were derived from DPK9 alone), and the light chain clones had between 1 and 49 mutations from their corresponding V germline genes. All 5 of the known J genes were used and were each joined to the DPK9 gene in one or more clones. Because the light chains showed considerably less diversity in their joining regions than the heavy chains, it was difficult to assign common clonal 
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For personal use only. on August 31, 2017. by guest www.bloodjournal.org From origins. However, an ontogeny tree was constructed by grouping common V and J gene segments along with common mutations (data not shown). Based on this analysis, the 18 chains comprised at least 10 different recombination events. light chains were restricted by their J gene usage but showed no restriction in their use of V genes (Fig 5) . The 23 light chains all used the J 2Vasicek gene but were derived from V I (12 clones), V III (5), V VII (3), V II (2), and V IV (1) family genes. The number of mutations ranged from 2 to 41 from the nearest germline V gene. Based on common joining regions and mutations, these 23 light chains were derived from at least 13 different B cells.
Assessment of the Diversity of the Unpanned Libraries
To determine whether the apparent restriction in gene usage of the anti-Rh(D) antibodies could have been due to preselection factors (ie, cloning artifacts), we assessed the diversity of the unpanned ␥ 1 and ␥ 1 Fab/phage libraries. By sequencing 39 randomly picked clones, we determined that there were no duplicate heavy or light chain sequences and that there was significant heterogeneity in V gene family representation before selection (Fig 6) . In fact, the variable region gene family distribution was not unlike that found by other investigators for IgG-secreting lymphocytes in adult peripheral blood. 33 Furthermore, of the 14 V H III-encoded negative clones, only one used a VH3-33 superspecies germline gene (VH3-30.3); the other 13 were encoded by VH3-07 (3), 3-09 (2), 3-15 (2), 3-48 (2), 3-72 (2), 3-23 (1), and DP-58 (1) . Therefore, the restriction of the 83 anti-Rh(D) clones to the VH3-33, 3-30, 3-30.3, and 3-21 genes is significant and not a result of skewed representation of certain germline genes within the originally constructed ␥ 1 and ␥ 1 Fab/phage libraries.
Heavy and Light Chain Contribution to Rh(D) Epitope Specificity
Because 6 (designated epitopes epD1, epD2, epD3, epD4, epD5, and epD6/7). Agglutination experiments with the Fab/phage clones showed five different patterns of reactivity, including a new pattern that had not been described in the original study by Lomas et al 6 or in the more recently described 9, 30, or 37 epitope systems (Figs 7 and 8). 3, 35 Although nearly all Fab/phage gave unequivocal agglutination reactions, a few antibodies gave repeatedly weak patterns of reactivity against one of the panel cells. For these reactions, monoclonal Fab/phage were prepared on at least four separate occasions to verify the patterns of reactivity.
The most commonly recognized epitope was epD6/7, against which 13 clones were directed. Interestingly, monoclonal anti-Rh(D) clones isolated using conventional tissue culture methods are most often specific for epD6/7. 34 epD2, epD1, and epD3 were recognized by 10, 7, and 2 clones, respectively. Six clones agglutinated cells of categories IIIa/c, IVa, and VII, but not of categories IVb, Va, and VI, and were designated anti-epDX. This pattern is identical to epD1, except that the IVa cell is agglutinated. Three clones gave intermediate reactions with cell IVa, but otherwise showed patterns consistent with epDX or epD1. These clones were designated epDX 1 or epD1 X , depending on whether this reactivity against cell IVa was stronger or weaker, respectively (Fig 8) . Similarly, reaction patterns for epD1 and epD2 differ by a positive reaction with the category Va cell; therefore, one clone was given epD2 1 specificity because it gave only moderate reactivity against that cell. Such variable reactions against one or more partial Rh(D) cells have been observed for anti-Rh(D) MoAbs produced through conventional tissue culture methods. 36 Because of the reassortment of heavy and light chain gene segments that occurs during the construction of a phage display library, a number of clones were isolated that shared either a heavy (eg, E1) or light (eg, M3) chain sequence (Fig 8) . Some heavy chains were found to have paired with both and light chains (eg, C1, D20), and each demonstrated anti-Rh(D) 
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. Interestingly, some heavy chains (eg, E1, D12) mapped to different epitopes depending on the light chains with which they were paired. In particular, the light chains of two such clones, E1/M2 and E1/M3, differed by only 3 amino acid residues (Fig 5) and these differences appear to confer specificity for epD2 versus epD3.
Inhibition Studies
To investigate the topological relationships among the Rh(D) epitopes, inhibition studies were performed. Previous work by Gorick et al 37 using pairs of unlabeled and 125 I-labeled antiRh(D) MoAbs demonstrated that antibodies to at least 3 different Rh(D) epitopes (subsequently identified as epD1, D6, and D7) 6 could inhibit one another. We have confirmed and extended these findings using recombinant antibodies to 5 Rh(D) epitopes (Fig 9) . In one series of experiments, we exploited the ability to express each antibody in both a soluble Fab as well as phage-displayed form to ask whether a soluble Fab against one epitope would inhibit the agglutination induced by an Fab/phage directed against a different epitope. Reciprocal pairs of soluble Fab and Fab/phage specific for epD1, epD2, epD3, epD6/7, and epDX were tested. All 10 combinations showed mutual inhibition patterns (shown in Fig 9A for an anti-epD3/anti-epD6/7 combination). To show that this inhibition was not due to nonspecific factors, a control with an irrelevant RBC-binding recombinant antibody (an anti-blood group B antibody) was performed (Fig 9B) . That sufficient inhibitory amounts of soluble Fab was present were first verified by demonstrating that each soluble Fab could inhibit its own Fab/phage (Fig 9A and B; samples on diagonal) . Similar results were obtained using pairs of soluble Fabs which differed in their light chain isotype composition (Fig 9C) .
Isoelectric Point (pI) Analysis of Anti-Rh(D) Antibodies
The restriction in V H germline gene usage to only four V H III family members was intriguing in light of their ability to confer specificity to a number of Rh(D) epitopes. As suggested by Boucher et al, 10 V H germline gene segments used to encode anti-Rh(D) antibodies are among the most cationic segments available in the human V H repertoire that may be used to account for the relatively high pI of polyclonal anti-Rh(D)-containing antisera. 38, 39 Although the cationic nature of the antibodies may be important for binding to Rh(D), it has also been suggested that a constitutive net positive charge may be necessary to permeate the highly negative RBC potential, thus permitting antibody to contact antigen. 34 In either case, analysis of the predicted pI for the 28 heavy chains and 41 light chains isolated here showed an interesting phenomenon for the heavy versus light chains. Using the pI interval scale of Boucher et al, 10 the average pI of the 4 germline V H segments used to encode the 28 heavy chains is high (9.87 Ϯ 0.15) and significantly higher than that of 39 randomly picked, non-Rh(D) binding clones from the original unpanned libraries (9.24 Ϯ 0.80, P Ͻ 10 Ϫ5 ). Similar to the results of Boucher et al, 10 the addition of D and J H segments and the introduction of somatic mutation did not significantly change the pI of the average 
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For personal use only. on August 31, 2017. by guest www.bloodjournal.org From anti-Rh(D) heavy chain (9.81 Ϯ 0.33, P Ͻ .37). However, for the light chains, the average pI of their germline counterparts was not cationic, but the light chains became so through the addition of J L segments and somatic mutation. Overall, for all 18 and 23 light chains, paired t-test analyses before and after somatic mutation showed a significant increase in net positive charge when comparing germline V L (6.63 Ϯ 1.47) with expressed V L (7.28 Ϯ 1.51, P Ͻ 10 Ϫ3 ) or germline V L J L (7.43 Ϯ showed that this increase in pI resulted from mutations that not only introduced positively charged residues, but also eliminated some negatively charged residues. There were 31 such events, 29 (91%) of which occurred in the light chain CDR regions.
DISCUSSION
Conventional and Phage-Displayed Anti-Rh(D) MoAbs
Because of differences in methodology, we were interested in comparing our phage-display-derived anti-Rh(D) clones with those produced by conventional tissue culture techniques (EBV transformation and cell fusion). Despite the relatively small number of previously published sequences for IgG anti-Rh(D) antibodies (N ϭ 21) and the fact that they were derived from over 10 different donors, 10, [23] [24] [25] there was surprisingly good correlation between the two groups ( Table 1) . Both cohorts demonstrated a predominance of V H III-family encoded germline genes, particularly those of the VH3-33 superspecies. CDR3 regions showed similar lengths, ranging from 15 to 19 residues for Fab/phage antibodies and 16 to 20 for conventional monoclonals, although one heterohybridoma was an outlier with a CDR3 length of 28 residues. light chains were biased towards V 1 family members and light chains demonstrated the preferential use of the J 2Vasicek gene. The only qualitative discrepancy was in V family usage, where Fab/phage clones demonstrated a slight preference for V I versus V III family members for conventional monoclonals. However, in both cohorts, DPL16 was used more often than any other light chain gene.
It has been suggested in the literature that the VH4-34 25 In a related series of experiments, we pooled aliquots of the ␥ 1 and ␥ 1 libraries obtained after the second and third rounds of selection and then panned them against the VH4-34 specific rat anti-idiotypic MoAb (9G4 44 ). Although we successfully enriched for VH4-34 encoded antibodies, the Fab/phage were not specific for Rh(D) and displayed serological characteristics similar to those of cold agglutinins (data not shown). We are currently examining a µ phage display library from the same donor to compare gene usage.
Rh(D) Epitopes and Significance of Antibody Sequences
Since the initial report by Argall et al 45 Fig 10A) would cause the loss of epD2. However, based on this concept of Rh(D) epitopes as distinct domains, we would expect that antibodies against different epitopes of Rh(D) would be structurally and genetically distinct as well. Thus, it was surprising that our anti-Rh(D) clones demonstrated such marked restriction in gene usage. For example, only two superspecies of V H genes were used despite specificities for 4 of the original 6 Rh(D) epitopes described by Lomas et al. 6 Furthermore, multiple specificities could arise from a single heavy chain depending on the light chain with which it was paired (eg, E1 with M2, M3, L3, or L4). In addition, other clones repeatedly 6 Note that inclusion of the category IVb cell (not available in our previous study) 22 permits the identification of a new epitope designated epDX (see text).
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For ) category RBCs that would affect the epitope specificities to which they were assigned (eg, C1 with O1, M1, or J5).
Several hypotheses could account for these findings. The most simplistic interpretation is that the heavy chain does not directly interact with the antigen, but rather is responsible for bringing the antibody in close proximity with the antigen. The specific interactions between the light chain and the antigen would then determine the epitope specificity for that antibody. In this regard, our data are consistent with the observations of Boucher et al 10 on the relative cationic nature of anti-Rh(D) heavy chains. However, because we found that light chains become cationic during somatic mutation, the charge of the entire antibody may play a role in its ability to bind, resulting in the selection and expansion of particular B-cell clones.
A more compelling hypothesis is that Rh(D) epitopes do not differ spatially but differ only in the number and arrangement of contact residues presented (Fig 10B) . In other words, the footprints of most, if not all, anti-Rh(D) antibodies are essentially identical to one another. The genetic events that produce partial Rh(D) molecules result in the loss of certain critical key points of contact necessary for some antibodies to bind; alternatively, they result in the formation of new structures that interfere with the binding of other anti-Rh(D) Igs. For example, the introduction of a ledge in Rh(D) category VI cells (asterisk, Fig 10B) does not interfere with the binding of an anti-epD3 antibody, but does prevent the binding of anti-epD2. Therefore, category VI RBCs are said to have epD3 but lack epD2.
This model is consistent with our inhibition experiments ( Fig  9) and with those of Gorick et al 37 and offers an explanation for the marked restriction in heavy chain gene usage. It also reconciles a mechanism by which one heavy chain (eg, E1) can confer binding to multiple epitopes and why some of our recombinant anti-Rh(D) antibodies, as well as some convention- 47 ) and how the residues associated with the expression of some epitopes appear to be distributed among nearly all the extracellular loops of Rh(D). 48 It also provides an understanding as to how Ն37 epitopes can fit on the relatively small extracellularly exposed surface of the Rh(D) molecule. 3 This concept of coincident epitopes is best exemplified by comparing the E1/M2 and E1/M3 clones. The only difference between the reactivity of E1/M2 and E1/M3 is the ability of the latter antibody to agglutinate Rh(D) category VI cells (Fig 7) . Hence, E1/M2 is classified as an anti-epD2 and E1/M3 as an anti-epD3 antibody. Light chains M2 and M3 differ by only 3 residues: D82A, G95aA, and W96V (Fig 5) . Therefore, some combination of these residues confers reactivity against category VI cells. In other words, epD2 and epD3, as seen by the E1/M2 and E1/M3 antibodies, differ by the binding constraints 23 Chouchane et al, 24 and Boucher et al 10 and available from Genbank. One light chain (Oak-3) 25 was not available in Genbank and was not included in the assessment.
†For heavy chains, the left column tabulates each clone separately and the right column tabulates clones on the basis of shared V-D-J joining regions.
‡VH3-33 superspecies defined as the group of VH3 family germline genes comprising VH3-33, VH3-30, and VH30.3. §CDR3 length outlier.
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For personal use only. on August 31, 2017. by guest www.bloodjournal.org From imposed by at most three mutations. If the model depicted in Fig  10A were correct and the epitopes were independent, these mutations would have to cause enough structural alteration in the antibody combining site so that a completely separate epitope on the same antigen would be recognized. It would seem unlikely that these 3 mutations could cause such a change, especially given the lack of internal homology domains in Rh(D). Thus, we conclude that it is far more plausible that the footprints of these 2 antibodies are essentially identical and that one or more of these mutations (eg, the tryptophan in CDR3 of M2) prevent(s) the interaction of E1/M2 with category VI RBCs. Because other clones demonstrate that the light chain can confer specificity against epD1, epD2, or epD3 (with the E1 heavy chain); epD1 or epDX (with C5); and epD1, epD2, and epD6/7 (with D12), we suggest that all 5 of these epitopes have similar antibody combining sites.
Immunologic and Clinical Implications of Proposed Model
The model depicted in Fig 10B leads 34 Therefore, an individual who produces category VI RBCs should be able to make anti-epD2 but not anti-epD3. If these epitopes were truly independent, then the immune repertoire of the anti-epD2 antibodies made by a category VI individual would be similar to those produced by an Rh(D)-negative person. However, to the immune system, epD2 and epD3 are not independent. We postulate that the somatic mutation of an anti-epD3 antibody can change its fine specificity to that of epD2 (or vice versa, Fig 10C) . Suppose that the preferred way of making an anti-epD2 antibody is to go through an anti-epD3 intermediate. To an Rh(D)-negative individual, this process can take place unimpeded. However, in a category VI individual, this route would be unfavorable because an anti-epD3 antibody would be self-reactive. As a result, such an individual would have to make anti-epD2 antibodies by following alternative routes or by tolerating some degree of autoreactivity in the process. With respect to the latter point, it is of interest to note that a transient production of auto-anti-Rh(D) frequently precedes or accompanies the early production of allo-anti-Rh(D) in individuals who express partial Rh(D) antigens. [49] [50] [51] [52] [53] [54] We would predict, therefore, that the anti-epD2 antibodies from a category VI individual would be different in composition (ie, gene usage) and quite possibly quantitatively depressed as compared with an Rh(D)-negative individual. This may be analogous to the antibodies of the ABO blood group system in which it has been observed that anti-A and anti-B titers in blood group O individuals are significantly higher than in blood group B or A individuals, respectively. 55 Blood group O individuals are unconstrained in creating their anti-A and anti-B immune repertoires, whereas individuals who produce A or B antigens (2 nearly identical structures) must do so in a manner that avoids self-reactivity.
In the case of antibodies E1/M2 and E1/M3, they appear to have arisen from a common precursor B cell rather than directly from each other (Fig 5) . To test the framework of our hypothesis, ie, somatic mutation resulting in epitope migration of an antibody, we are constructing the precursors and potential intermediates between the M2 and M3 light chains and will then determine what Rh(D) epitope specificities (if any) they express. This concept of epitope migration has been previously reported for murine anti-cryptococcal 56 and anti-type II collagen 57 antibodies.
If the proposed model for Rh(D) epitopes is correct, then the In summary, we have studied the genetic and immunological properties of a large array of anti-Rh(D) antibodies to elucidate this clinically significant human immune response on a molecular level. Our results show that anti-Rh(D) antibodies display a high degree of structural relatedness and the ability to inhibit each other's binding despite differences in epitope specificity. These findings suggest that Rh(D) epitopes are not spatially distinct and that Rh(D) antibodies may undergo epitope migration as a result of somatic mutation. The end result is that the prevalence of certain anti-Rh(D) specificities in the immune repertoire may be a function not only of what epitopes an individual lacks, but of the number of accessible pathways that the individual's immune system can use that avoid selfreactivity. This process may be a general feature of human immune responses to other clinically significant, closely related epitopes.
